Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer

Senior Research Fellow



+44 (0)20 7594 2808l.magnani CV




140ICTEM buildingHammersmith Campus






BibTex format

booktitle = {Breast Cancer: Innovations in Research and Management},
doi = {10.1007/978-3-319-48848-6_3},
pages = {19--26},
title = {Fundamental pathways in breast cancer 3: Estrogen biology},
url = {},
year = {2017}

RIS format (EndNote, RefMan)

AB - © Springer International Publishing AG 2017. Over the last two decades, it has become evident that breast cancer should be considered as a family of diseases rather than as a unique malignancy. Pathological, molecular, and genetic analysis have revealed the existence of five to ten main subgroups [1-3]. Over 70% of all patients are generally classified by the tumor dependencies on estrogenic compounds [4]. These dependencies are principally mediated by the nuclear receptor estrogen receptor a (ERa) [5, 6]. For all these reasons, ERa remains the key driver in the majority of breast cancers and is commonly used as a molecular biomarker for stratification while serving as the main target for systemic adjuvant chemotherapy. In this chapter I will discuss the molecular mechanisms of ERa activation focusing on integrative analysis that have recently exposed the intimate link between ERa and chromatin structure.
DO - 10.1007/978-3-319-48848-6_3
EP - 26
PY - 2017///
SN - 9783319488486
SP - 19
TI - Fundamental pathways in breast cancer 3: Estrogen biology
T1 - Breast Cancer: Innovations in Research and Management
UR -
ER -